Are you struggling to find CDMO capacity? Here are some of the drivers behind the contract manufacturing market's exponential growth.
- Single Use In Biopharma: Beyond Savings & Sustainability
- Unpacking The Importance Of Lipid Nanoparticle Production Platforms
- Cell Counting Is Growing More Important Amid Advanced Therapy’s Rise
- FDA Publishes Final Guidance On Reporting Listed Drug Amounts
- 2024 CIO Survey Reveals IT Budgets, AI Priorities For Life Sciences Companies
- AI And Pharmaceutical Development: WHO Calls For Ethical Framework, Good Governance
- Digitizing CMC Knowledge Management
EDITOR'S DESK
-
Doubling Down On Biopharma’s Growing Skills Drought
The biopharmaceutical industry is building manufacturing capacity at breakneck speed. According to PhRMA, there are 1,580-and-counting biopharma manufacturing facilities in the U.S. alone. Problem is, we're way short on filling those facilities with skilled labor. NIIMBL wants to change that. Here's how, and a great opportunity for big pharma, biotech sponsors, CDMOs, academics, and more to help.
The career of Debra Weiss, RN, MSN, and COO at the biopharma Gates Medical Research Institute (Gates MRI), offers a case study in creating success through service-oriented leadership.
Check out the results of DeciBio's Antibody-Drug Conjugates 2024 Industry Survey, which predict another bullish year for the growing modality.
The U.S. imported $6.95 billion worth of pharmaceuticals from China in 2022. That was 8x the amount we imported in 2021. A proposed Act of Congress puts that supply, and U.S. biotech itself, in serious peril.
In the U.K., a professor at the University of Birmingham is using virtual reality (VR) to help address the growing biomanufacturing skills shortage — using virtual reality (VR).
GUEST COLUMNISTS
-
Unpacking The Importance Of Lipid Nanoparticle Production Platforms
Batch processing platforms for LNPs lack efficiency, appropriate controls, and yield optimization. Continuous manufacturing platforms may address some of those issues.
-
Cell Counting Is Growing More Important Amid Advanced Therapy’s Rise
You can't improve what you don't measure. This discussion explores advances in cell counting technology and the growing number of ways it aids the biotech industry and beyond.
-
FDA Publishes Final Guidance On Reporting Listed Drug Amounts
Despite earlier efforts to shore up the U.S. drug supply chain, COVID-19 still brought shortages. A new FDA reporting system aims to reduce future supply risks.
-
2024 CIO Survey Reveals IT Budgets, AI Priorities For Life Sciences Companies
Clarkston Consulting conducted its third annual Chief Information Officer (CIO) Survey to understand IT budgets of life sciences companies, how AI priorities fit into those budgets, and more.
-
AI And Pharmaceutical Development: WHO Calls For Ethical Framework, Good Governance
The World Health Organization (WHO) recently released a document titled Benefits and risks of using artificial intelligence for pharmaceutical development and delivery describing the ethical issues and governance considerations for using AI in drug discovery, preclinical development, and clinical trials.
-
Digitizing CMC Knowledge Management
Systems that enhance know-how retention stretch from utterly simple to enterprise-scale. Here are some ideas for incorporating them into your knowledge management strategy.
-
Managing Supply Chain Risks Using Relational Risk Analysis
In the bio/pharma and medical device industries, you can easily model, understand, and manage supply chain risks using relational risk analysis. Here's how.
-
When Does GMP Matter In Non-GMP Settings?
Would you ever need to follow GMP standards in workspaces where GMP is not required or possible? This article digs into why, when, and how to follow the principles of GMP.
BIOPROCESSING WHITE PAPERS
-
Biosafety Testing And Quality Control Requirements For Lentiviral Vectors
Learn more about manufacturing principles of LV vectors as well as testing requirement regulatory considerations with a particular focus on the replication competent virus assay and infectious titer assay.
-
Successful Planning: Process Liquid & Buffer Preparation6/23/2023
Obtain an accurate total cost of ownership assessment through understanding common operational inefficiencies, risks, and financial burdens associated with process liquid and buffer preparation.
-
State-Of-The-Art Bispecific Antibody Development10/11/2022
The promise of bispecific antibodies stems from their off-the-shelf nature and ability to bind to two or more different targets or epitopes, thereby performing multiple functions.
-
An Experienced CDMO Can Be A Differentiator In The Rapidly Growing Biologics Market12/14/2023
Biotech and biopharma developers are increasingly relying on outsourcing partners to meet both clinical and commercial research, development, and production needs. CDMOs that provide end-to-end services, including secure supply chains, can help biologics developers meet accelerated timelines and establish a real competitive advantage in today’s competitive market.
-
Manual vs. Automated Labware Washing7/7/2023
Compare manually washed labware and labware cleaned in automatic washing systems, to see how the challenges of manual washing can impact your labs efficacy and repeatability.
-
Taking Charge Of Your Stability Program10/5/2022
Conducting stability studies is a critical aspect of the drug development process. Learn how consolidating stability testing with a single partner offers improved efficiency, reduced risk, and more.
BIOPROCESSING APP NOTES & CASE STUDIES
- SPR Assays To The Assess Similarity Between Innovator And Biosimilar Versions of Nivolumab (Opdivo®)
- Secondary Packaging Strategies For Commercial Launch Of A Biologic
- DNA Purification From PCR Or Agarose Gels
- Capsules Versus Hollow Fibers For Ultrafiltration/Diafiltration (UF/DF)
- Democratizes Batch Data Management For AAV Gene Therapies And Accelerates CMO Collaboration
BIOPROCESS ONLINE CONTENT COLLECTIONS
This collection of articles, produced through a partnership between MilliporeSigma and Bioprocess Online, highlights the need for ongoing investment in resilient biomanufacturing capacity and supply chains to ensure the reliable delivery of health technologies like vaccines, even during crisis conditions.
More Content CollectionsFEATURED PRODUCTS AND SERVICES
ON-DEMAND WEBINARS
- Culturing And Characterizing Organoids And Cancer Spheroids
- How To Get Started With Organ-On-A-Chip Technology
- De-Risking The Aseptic Drug-Filling Process And Optimizing Production
- ChipChat With Emulate: Answering Your Organ-Chip Questions Live
- Assessing Reproductive Health With A Human Vagina-On-A-Chip
INDUSTRY NEWS
NEWSLETTER ARCHIVE
- 04.19.24 -- Developing & Implementing A Continuous Bioprocess Control Strategy
- 04.18.24 -- Bringing Therapies To Patients With Speed And Confidence
- 04.18.24 -- Process Mapping For More Effective Knowledge Management
- 04.17.24 -- Optimizing Drug Delivery Systems For Complex Biologics
- 04.17.24 -- Leverage Innovative Assays And Monitoring To Improve mAb Production